Research programme: interleukin 1 beta inhibitors - Opsona

Alternative Names: IL1-ß inhibitor - Opsona

Latest Information Update: 03 Feb 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Opsona Therapeutics
Class Small molecules
Mechanism of Action Interleukin 1 beta inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Inflammation

Highest Development Phases

Research Inflammation

Most Recent Events

03 Feb 2017 The interleukin 1 beta inhibitor research programme is still under early research for Inflammation in Ireland (Opsona Therapeutics pipeline, February 2017)
03 Feb 2017 Research programme: interleukin 1 beta inhibitors - Opsona is available for licensing/partnering as of 03 Feb 2017. http://www.opsona.com/Inflammasome
16 Jul 2016 No recent reports of development identified for research development in Inflammation in Ireland

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.